NCT06597526 is a clinical trial in Peritoneal Metastasis, sponsored by Ruijin Hospital.

Who is sponsoring NCT06597526?

NCT06597526 is sponsored by Ruijin Hospital.

What condition does NCT06597526 study?

NCT06597526 studies Peritoneal Metastasis, Gastric Cancer.

Is NCT06597526 still recruiting?

NCT06597526 is currently recruiting now. Last updated 19 September 2024.

Last reviewed 2024-09-19 · How we verify

NCT06597526

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Role of 18F-FDG&68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastasis.

Recruiting now Last updated 19 September 2024

What this trial tests

trial in Peritoneal Metastasis in 30 participants. Currently enrolling.

Timeline

15 June 2024

Primary endpoint
31 March 2028

31 May 2029

Quick facts

Lead sponsor	Ruijin Hospital
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	30
Start date	15 June 2024
Primary completion	31 March 2028
Estimated completion	31 May 2029
Sites	1 location across China

Conditions studied

Peritoneal Metastasis — all drugs for Peritoneal Metastasis →
Gastric Cancer — all drugs for Gastric Cancer →

Sponsor

Ruijin Hospital

Who can join

18 and older, any sex, with Peritoneal Metastasis or Gastric Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to investigate the value of 18F-FDG\&68Ga-FAPI PET/CT in evaluating the outcome of conversion therapy and the prognosis of people with peritoneal metastases from gastric cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Peritoneal Metastasis

Currently open trials in the same condition.

NCT06940921 — SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases · Phase 1, PHASE2 · active not recruiting

Other Ruijin Hospital trials

Trials by the same sponsor.

NCT07589361 — Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors · not yet recruiting
NCT07449507 — Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy · NA · not yet recruiting
NCT07496385 — Clinical Study on the Efficacy of Subglottic Suction in Mechanically Ventilated Patients Guided by Bedside Ultrasound · NA · not yet recruiting
NCT07511114 — A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyp · Phase 3 · not yet recruiting
NCT07514169 — The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06597526 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ruijin Hospital
Last refreshed: 19 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06597526.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing